Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune-mediated neuropathies

A J Kornberg1, A Pestronk

  • 1Washington University School of Medicine, Department of Neurology, St. Louis, MO 63110.

Current Opinion in Neurology
|October 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unclassified white matter disorders: A diagnostic journey requiring close collaboration between clinical and laboratory services.

European journal of medical genetics·2022
Same author

Correction: Targeted gene correction in the mdx mouse using short DNA fragments: towards application with bone marrow-derived cells for autologous remodeling of dystrophic muscle.

Gene therapy·2021
Same author

Acute flaccid myelitis in childhood: a retrospective cohort study.

European journal of neurology·2017
Same author

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Journal of neurology, neurosurgery, and psychiatry·2015
Same author

Observations of body mass index in Duchenne muscular dystrophy: a longitudinal study.

European journal of clinical nutrition·2014
Same author

Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy.

Neurology·2012
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Identifying immune-mediated neuropathies is crucial for effective treatment. Autoantibodies and M proteins serve as diagnostic markers for specific polyneuropathy syndromes, guiding therapy choices.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Diagnostics

Background:

  • Immune-mediated neuropathies often require specific treatments.
  • Accurate diagnosis is key to selecting appropriate immunosuppressive therapies.

Purpose of the Study:

  • To highlight the importance of identifying immune-mediated neuropathies.
  • To establish serum M proteins and autoantibodies as diagnostic markers for polyneuropathy syndromes.

Main Methods:

  • Analysis of serum M protein and autoantibody binding patterns.
  • Correlation of antibody profiles with specific polyneuropathy syndromes.

Main Results:

  • Observed correlations between M protein/autoantibody binding and specific polyneuropathy syndromes.

Related Experiment Videos

  • Evidence suggesting a pathogenic role for certain autoantibodies in these conditions.

    • Conclusions:

    • Identification of immune-mediated polyneuropathy syndromes is clinically significant.
    • Specific antibody profiles can guide the selection of immunosuppressive treatments for improved patient outcomes.